JP5679992B2 - 複合体および生産方法 - Google Patents

複合体および生産方法 Download PDF

Info

Publication number
JP5679992B2
JP5679992B2 JP2011544926A JP2011544926A JP5679992B2 JP 5679992 B2 JP5679992 B2 JP 5679992B2 JP 2011544926 A JP2011544926 A JP 2011544926A JP 2011544926 A JP2011544926 A JP 2011544926A JP 5679992 B2 JP5679992 B2 JP 5679992B2
Authority
JP
Japan
Prior art keywords
lactalbumin
recombinant protein
biologically active
complex
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011544926A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012514466A5 (https=
JP2012514466A (ja
Inventor
ペーテルソン−カストバーグ、ジェニー
スヴァンボルグ、カタリナ
ハン モック、ケネス
ハン モック、ケネス
モスベルグ、アン−クリスティン
Original Assignee
ハムレット・ファルマ・アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0900260A external-priority patent/GB0900260D0/en
Priority claimed from GB0906199A external-priority patent/GB0906199D0/en
Application filed by ハムレット・ファルマ・アーベー filed Critical ハムレット・ファルマ・アーベー
Publication of JP2012514466A publication Critical patent/JP2012514466A/ja
Publication of JP2012514466A5 publication Critical patent/JP2012514466A5/ja
Application granted granted Critical
Publication of JP5679992B2 publication Critical patent/JP5679992B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2011544926A 2009-01-09 2010-01-08 複合体および生産方法 Active JP5679992B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0900260A GB0900260D0 (en) 2009-01-09 2009-01-09 Complex and production process
GB0900260.1 2009-01-09
GB0906199A GB0906199D0 (en) 2009-04-09 2009-04-09 Complex and production process
GB0906199.5 2009-04-09
PCT/GB2010/050024 WO2010079362A1 (en) 2009-01-09 2010-01-08 Complex and production process

Publications (3)

Publication Number Publication Date
JP2012514466A JP2012514466A (ja) 2012-06-28
JP2012514466A5 JP2012514466A5 (https=) 2013-02-28
JP5679992B2 true JP5679992B2 (ja) 2015-03-04

Family

ID=42026257

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011544926A Active JP5679992B2 (ja) 2009-01-09 2010-01-08 複合体および生産方法

Country Status (8)

Country Link
US (1) US8796218B2 (https=)
EP (1) EP2385954B1 (https=)
JP (1) JP5679992B2 (https=)
CN (1) CN102348721A (https=)
AU (1) AU2010204178B2 (https=)
CA (1) CA2752490C (https=)
DK (1) DK2385954T3 (https=)
WO (1) WO2010079362A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8796218B2 (en) 2009-01-09 2014-08-05 Hamlet Pharma Ab Complex and production process
ES2613986T3 (es) 2010-11-24 2017-05-29 Hamlet Pharma Ab Complejo biológicamente activo y su preparación
HUE038910T2 (hu) 2012-08-09 2018-12-28 Hamlet Pharma Ab Profilaktikus és gyógytáp terápia
CN106636157A (zh) * 2016-09-01 2017-05-10 锦州医科大学 一种突变α‑乳清蛋白表达载体、制备方法及其应用
GB201621752D0 (en) * 2016-12-20 2017-02-01 Hamlet Pharma Ab Therapeutically active complexes
GB201707715D0 (en) * 2017-05-14 2017-06-28 Hamlet Pharma Ab Preperation of biologically active complexes
WO2021032807A1 (en) 2019-08-20 2021-02-25 Hamlet Pharma Ab Combination of a chemotherapeutic agent and alpha-lactoglubulin-oleic acid complex for cancer therapy
GB202015836D0 (en) 2020-10-06 2020-11-18 Hamlet Pharma Ab Compositions
GB202303177D0 (en) 2023-03-03 2023-04-19 Linnane Pharma Ab Method of predicting response to treatment
WO2025186107A1 (en) 2024-03-04 2025-09-12 Linnane Pharma Ab Therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1032596T3 (da) 1997-11-21 2007-09-10 Nya Hamlet Pharma Ab Fremgangsmåde til fremstilling af lactalbumin
GB9725126D0 (en) 1997-11-27 1998-01-28 Svanborg Catharina Therapeutic agents
AU5928599A (en) 1999-09-09 2001-04-10 Efa Sciences Llc. Methods for treating cell proliferative disorders including cancer
US6639089B2 (en) 2000-11-08 2003-10-28 Soda Aromatic Co., Ltd. Anticancer agents, perfumes or foods and drinks
GB0205347D0 (en) 2002-03-07 2002-04-24 Svanborg Catharina Biologically active complex
GB0508880D0 (en) * 2005-05-03 2005-06-08 Hamlet Pharma Ab Novel therapies and methods of screening for therapeutic compounds
US20080115228A1 (en) * 2006-11-15 2008-05-15 Yahoo! Inc. Rights engine
EP2094309A2 (en) 2006-11-17 2009-09-02 Nya Hamlet Pharma AB Alpha-lactalbumin composition
WO2008138348A1 (en) * 2007-05-09 2008-11-20 Nya Hamlet Pharma Ab Preparation of complexed lactalbumin
US8796218B2 (en) 2009-01-09 2014-08-05 Hamlet Pharma Ab Complex and production process
WO2010131237A1 (en) 2009-05-13 2010-11-18 Agriculture And Food Development Authority (Teagasc) A process for producing a biologically active globular protein complex
ES2613986T3 (es) 2010-11-24 2017-05-29 Hamlet Pharma Ab Complejo biológicamente activo y su preparación

Also Published As

Publication number Publication date
EP2385954B1 (en) 2013-04-03
WO2010079362A1 (en) 2010-07-15
CA2752490C (en) 2020-03-10
US20120028883A1 (en) 2012-02-02
DK2385954T3 (da) 2013-06-17
EP2385954A1 (en) 2011-11-16
AU2010204178B2 (en) 2015-10-29
JP2012514466A (ja) 2012-06-28
AU2010204178A1 (en) 2011-09-01
US8796218B2 (en) 2014-08-05
CN102348721A (zh) 2012-02-08
CA2752490A1 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
JP5679992B2 (ja) 複合体および生産方法
Rangachari et al. Amyloid-β (1− 42) rapidly forms protofibrils and oligomers by distinct pathways in low concentrations of sodium dodecylsulfate
Gill et al. Post‐translational hydroxylation at the N‐terminus of the prion protein reveals presence of PPII structure in vivo
Moore et al. Biophysical analyses of synthetic amyloid-β (1− 42) aggregates before and after covalent cross-linking. implications for deducing the structure of endogenous amyloid-β oligomers
Fisher et al. Bacterial overexpression, isotope enrichment, and NMR analysis of the N-terminal domain of human apolipoprotein E
KR20190092472A (ko) 나노입자 제제
Ramirez et al. Nuclear magnetic resonance-based structural characterization and backbone dynamics of recombinant bee venom melittin
Alamo et al. Rational engineering of a human GFP-like protein scaffold for humanized targeted nanomedicines
CN107325168B (zh) 一种经修饰的生长分化因子及其制备方法和应用
Francis et al. The single C‐terminal helix of human phospholipid scramblase 1 is required for membrane insertion and scrambling activity
US20080167233A1 (en) Active complex of alpha-lactalbumin (HAMLET) and cofactor
US20060229436A1 (en) Lactalbumin production process
JP2020519278A (ja) 高ホモシステイン血症およびホモシスチン尿症の患者を処置するための、ヒト酵素介在性のホモシステイン枯渇
Bascetin et al. Amyloid-like aggregates formation by blood plasma fibronectin
KR100486472B1 (ko) 폰빌레브란트인자의치료성단편
WO2003074547A2 (en) Biologically active complex comprising alpha-lcatalbumin or a variant thereof, and a cofactor
Bonde et al. Random mutagenesis of amelogenin for engineering protein nanoparticles
West et al. Purification and characterization of the creatine transporter expressed at high levels in HEK293 cells
Ion et al. SDS-induced Peptide Conformational Changes: From Triglycyl-glycine to Amyloid-β Oligomers Associated with Alzheimer’s Disease
Guimarães et al. Optimizing the synthesis of dimeric peptides: influence of the reaction medium and effects that modulate kinetics and reaction yield
JP2020531516A (ja) フォン・ウィルブランド因子のウイルスろ過の方法
WO2020089912A1 (en) Anti-biofilm compositions
Esmaili Polymer-Based Nanodiscs for Structural and Functional Analyses of Bacterial and Mammalian Membrane Proteins
KR102684366B1 (ko) 반월판 재생용 재료
Shilton et al. Cherry Lin1, Michael Miller1, Geetha Veeramuthu1, Jeff Pucci1, Shauna Bowden1 1Dupont, USA

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140903

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141209

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150106

R150 Certificate of patent or registration of utility model

Ref document number: 5679992

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250